-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HCW-9201 in Myelodysplastic Syndrome
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.HCW-9201 in Myelodysplastic Syndrome Drug Details:HCW-9201 is under investigation for the treatment of relapsed or refractory...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Selicrelumab in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Selicrelumab in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Selicrelumab in B-Cell Non-Hodgkin Lymphoma Drug Details: Selicrelumab is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HCW-9218 in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HCW-9218 in Metastatic Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.HCW-9218 in Metastatic Pancreatic Cancer Drug Details:HCW-9218 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HCW-9201 in Relapsed Acute Myeloid Leukemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.HCW-9201 in Relapsed Acute Myeloid Leukemia Drug Details:HCW-9201 is under investigation for the treatment of relapsed...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Posoleucel in Epstein–Barr Virus (HHV-4) Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Posoleucel in Epstein–Barr Virus (HHV-4) Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Posoleucel in Epstein–Barr Virus (HHV-4) Infections Drug Details: Posoleucel (ALVR-105)...
-
Product Insights
NewDermatological Disorders – Drugs In Development, 2024
Empower your strategies with our Dermatological Disorders – Drugs In Development, 2024 report and make more profitable business decisions. Dermatological disorders are diseases or conditions that affect the skin, hair, or nails. They can have various causes, symptoms, and treatments. Some of the most common dermatological disorders are acne, eczema, psoriasis, rosacea, and warts. Dermatologists are doctors who specialize in diagnosing and treating these disorders. Dermatological disorders can affect the appearance, function, and quality of life of the patients. Some of...
-
Product Insights
NewAlopecia Areata – Drugs In Development, 2024
Empower your strategies with our Alopecia Areata – Drugs In Development, 2024 report and make more profitable business decisions. Alopecia areata is an autoimmune condition characterized by unpredictable, patchy hair loss. It occurs when the immune system mistakenly attacks hair follicles, leading to hair loss in small, round patches on the scalp or other parts of the body. In some cases, it can progress to total hair loss (alopecia totalis) or loss of hair on the entire body (alopecia universalis). The...
-
Product Insights
NewRectal Cancer – Drugs In Development, 2024
Empower your strategies with our Rectal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Rectal cancer affects the lower part of the colon, which connects the large bowel to the anus. The risk factors for developing rectal cancer are increasing age, smoking, family history of colon or rectal cancer, high-fat diet and/or a diet mostly from animal sources, and personal or family history of polyps or colorectal cancer. Rectal cancer commonly spreads to organs such as...
-
Product Insights
NewArteriosclerosis – Drugs In Development, 2024
Empower your strategies with our Arteriosclerosis – Drugs In Development, 2024 report and make more profitable business decisions. Arteriosclerosis refers to the thickening and hardening of arteries due to plaque buildup, limiting blood flow. Atherosclerosis, a common form, involves cholesterol and other substances accumulating in arterial walls, narrowing them. This condition heightens the risk of heart disease, stroke, and peripheral artery disease. Factors like high blood pressure, cholesterol, smoking, diabetes, and obesity contribute. Management involves lifestyle changes—such as a healthy diet...